glp-1 nasal ring Limited evidence for anatomical contacts between intestinal cells and vagal neurons in male mice Designing GLP-1 delivery: structural perspectives

Some patients on GLP-1 medications have reported changes in mood or fatigue

Unfortunately, most people find it difficult to lose the weight they need to improve NAFLD and much more challenging to keep it off

Fatigue or mild headache may occur in some patients during the first day, though these symptoms are less common than gastrointestinal effects

This article aims to provide an overview of GLP-1 based drugs, focusing on semaglutide (marketed as Ozempic for type 2 diabetes and as Wegovy for obesity) and tirzepatide (marketed as Mounjaro), which is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 agonist

Neither is healthy weight loss swiftly attained